Endometrial hyperplasia and the risk of coexistent cancer: WHO versus EIN criteria by Travaglino, Antonio et al.
REVIEW
Endometrial hyperplasia and the risk of coexistent cancer:
WHO versus EIN criteria
Antonio Travaglino,1 Antonio Raffone,2 Gabriele Saccone,2 Antonio Mollo,2
Giuseppe De Placido,2 Luigi Insabato1 & Fulvio Zullo2
1Anatomical Pathology Unit, Department of Advanced Biomedical Sciences, School of Medicine, University of Naples
Federico II, and 2Gynaecology and Obstetrics Unit, Department of Neuroscience, Reproductive Sciences and Dentistry,
School of Medicine, University of Naples Federico II, Naples, Italy
Date of submission 8 August 2018
Accepted for publication 17 October 2018
Published online Article Accepted 22 October 2018
Travaglino A, Raffone A, Saccone G, Mollo A, De Placido G, Insabato L & Zullo F
(2019) Histopathology 74, 676–687. https://doi.org/10.1111/his.13776
Endometrial hyperplasia and the risk of coexistent cancer: WHO versus EIN criteria
Endometrial hyperplasia (EH) is classified into benign
and precancerous according to two different histomor-
phological systems: the World Health Organisation
(WHO) system (based on the subjective evaluation of
cytological atypia) and the endometrial intraepithelial
neoplasia (EIN) system (based on a combination of sev-
eral parameters that are assessable subjectively, or
objectively through computerised analysis). The Ameri-
can College of Obstetricians and Gynecologists recom-
mends use of the EIN system. Nonetheless, a higher
prognostic value for EIN criteria was demonstrated
only with the objective assessment, which is not rou-
tinely applicable. The aim of this study was to evaluate
which of the subjective classifications of EH (WHO or
EIN) has better prognostic value, by assessing the risk
of coexistent cancer. Electronic databases were
searched for relevant articles from the inception of the
databases to July 2018. All studies assessing the pres-
ence of cancer on hysterectomy specimens after a
preoperative histological diagnosis of EH were included.
Odds ratios (ORs), sensitivity and specificity were calcu-
lated with 95% confidence intervals (CIs). Sixteen
cohort studies and three case–control studies, assessing
2582 EHs, were included. The WHO criteria showed
an OR of 11.15 (95% CI 7.65–16.24), a sensitivity of
0.86 (95% CI 0.82–0.90) and a specificity of 0.67
(95% CI 0.64–0.70) for coexistent cancer. The subjec-
tive EIN system showed a similar OR (11.85, 95% CI
4.91–28.62; P = 0.90), higher sensitivity (0.98, 95%
CI 0.94–0.99), and lower specificity (0.29, 95% CI
0.24–0.34). The WHO system and the subjective EIN
system have similar prognostic values. However, the
EIN criteria appear to be more sensitive and thus more
suitable for selecting women who need to be treated,
whereas the WHO criteria, based on cytological atypia,
seem to be more specific for lesions at higher risk of
cancer. Therefore, integration of the EIN system with
cytological atypia should be considered.
Keywords: concurrent cancer, endometrial intraepithelial neoplasia, endometrial precancer, endometrioid
adenocarcinoma, prognosis, World Health Organization
Introduction
Endometrial hyperplasia (EH) is a hyperproliferative
condition characterised by an increased gland to
stroma ratio as compared with proliferative endo-
metrium.1,2 EH includes polyclonal proliferations
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caused by the unopposed action of oestrogens, and
neoplastic lesions that can progress to endometrioid
adenocarcinoma.2,3 Differentiating between these two
possibilities is crucial in order to choose an adequate
treatment. In fact, women diagnosed with premalig-
nant EH should undergo hysterectomy, whereas a
conservative progestin-based treatment can be consid-
ered in selected cases (a strong wish to preserve fertil-
ity; contraindications to surgery). On the other hand,
benign EH can be managed by observation alone or
with progestins when symptomatic.3,4
The differential diagnosis is made by histological
examination, although no consensus has been
achieved in the literature on the criteria for defining
premalignancy.2,5
The most widely used classification system is the one
proposed by the World Health Organisation (WHO) in
1994 and revised in 2014, which differentiates
between premalignant and benign EH on the basis of
the presence of cytological atypia.1,2 The WHO system
has been criticised because of its low reproducibility
and the lack of a pathogenic and molecular basis.3,5,6
For this reason, an alternative system [the endometrial
intraepithelial neoplasia (EIN system] has been pro-
posed to improve the differential diagnosis.2,3,5–8
The EIN system separates EH into benign EH and
EIN, according to a combination of morphological
parameters that are assessable objectively or subjec-
tively. The objective EIN criteria are based on a com-
puterised morphometric analysis of gland to stroma
ratio, glandular perimeter, and nuclear diameter,
allowing the calculation of a prognostic score (D-
score).6–8 The subjective EIN criteria include gland to
stroma ratio, cytological differences from the adjacent
endometrium, lesion dimensions, exclusion of mimics,
and cancer.3,5
The Royal College of Obstetricians and Gynaecolo-
gists (RCOG) recommends use of the WHO system for
diagnosing premalignant EH,4 whereas the American
College of Obstetricians and Gynecologists (ACOG)
recommends use of the EIN system,9 because several
studies have shown that it predicts the risk of pro-
gression to cancer better than the WHO system.6–8
However, in most cases these results referred to the
objective D-score calculation, which is not widely
available in common practice. For the routinely appli-
cable subjective EIN criteria, evidence of superiority
over the WHO system is lacking. Thus, it is unclear
whether the ACOG recommendation may actually
improve the diagnosis of EH.
Unfortunately, it is difficult to draw conclusions
from the literature regarding the prognostic value of
the two systems, as the rates of progression to cancer
reported in the several studies are strongly influenced
by the duration of follow-up.6,10
Several authors have assessed the prognostic value
of one or both classification systems by considering
the rate of coexistent cancer on hysterectomy speci-
mens after a preoperative diagnosis of EH.11–29 This
allows data from different studies to be compared,
eliminating the confounding due to the varying dura-
tions of follow-up.
Thus, the main aim of our study was to determine
which subjective classification system for EH (WHO
or EIN) has a better prognostic value, based on the
rate of coexistent cancers.
Materials and Methods
S T U D Y P R O T O C O L
This study followed a recommended protocol for sys-
tematic review and meta-analysis. Methods for collec-
tion, extraction and analysis of data were designed a
priori. All review stages, including risk of bias assess-
ment, were conducted independently by two review-
ers (A.T. and A.R.). Disagreements were resolved by
discussion with a third reviewer (G.S.).
The study was reported following the Preferred
Reporting Item for Systematic Reviews and Meta-ana-
lyses (PRISMA) statement.30
S E A R C H S T R A T E G Y
MEDLINE, EMBASE, Web of Sciences, Scopus, Clini-
calTrial.gov, OVID, the Cochrane Library and Google
Scholar were searched for relevant articles from the incep-
tion of these databases to July 2018, by use of a combina-
tion of the following text words found in Medical Subject
Headings (MeSH): ‘endometr*’; ‘hyperplasia’; ‘intraepithe-
lial neoplasia’; ‘EIN’; ‘WHO’; ‘cancer’; ‘adenocarcinoma’;
‘precancer’; ‘premalignant’; ‘precursor’; ‘concurren*’;
‘coexisten*’; ‘predict*’; ‘prognos*’; ‘progression’; ‘develop-
ment’; ‘risk’; and ‘hysterectomy’. References from relevant
articles were also reviewed.
S T U D Y S E L E C T I O N
We included all peer-reviewed, retrospective or
prospective studies assessing the presence of occult
endometrial cancer in patients preoperatively diag-
nosed with EH and who underwent hysterectomy.
Exclusion criteria were: (i) latency time from EH diag-
nosis to hysterectomy of >1 year; (ii) presence of can-
cer assessed by endometrial sampling and not by
hysterectomy; (iii) inclusion of only benign or only
© 2018 John Wiley & Sons Ltd, Histopathology, 74, 676–687.
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premalignant EH; (iv) classification system other than
the WHO system or the EIN system; (v) EIN criteria
assessed solely through morphometric analysis; (vi)
total sample size of <20 EHs or sample size of <10 in
each EH category; (vii) reviews; and (viii) overlapping
patient data with those of a study already included.
Reasons for exclusion are detailed in Data S1A. No
language restrictions were applied.
R I S K O F B I A S A S S E S S M E N T
The risk of bias was assessed according to the revised
Quality Assessment of Diagnostic Accuracy Studies 2
(QUADAS-2).31 In each study, four domains related to
risk of bias were assessed, and, for each domain, the
authors’ judgement was ‘low risk’, ‘high risk’ or ‘un-
clear risk’ of bias: (i) patient selection (low risk if consec-
utive patients were included, a case–control design was
avoided, and inappropriate exclusions were avoided);
(ii) index test (low risk if EH categorisation was made
blinded to the results of hysterectomy examination); (iii)
reference standard (low risk if the presence of cancer on
hysterectomy specimen was assessed blinded to the EH
category); and (iv) flow and timing (low risk if all
patients underwent hysterectomy within 1 year from
the index test). For each domain, high risk of bias was
assigned if any criterion was not met. If study data did
not allow assessment of the risk of bias, unclear risk of
bias was assigned. Concerns about applicability of
domains 1, 2 and 3 were also assessed (i.e. if study
methods did not suit the objective of our review, regard-
less of their correctness) and categorised as ‘low’, ‘un-
clear’ and ‘high’ concerns about applicability.
D A T A E X T R A C T I O N
Data were extracted from each included study with-
out modifications. Two-by-two contingency tables
were prepared for each study, reporting two dichoto-
mous qualitative variables: (i) EH category at histo-
logical examination of preoperative biopsy (‘benign’
or ‘premalignant’); and (ii) presence of occult cancer
on hysterectomy specimen (‘no cancer’ or ‘cancer’).
For the studies using the WHO criteria, EH without
atypia (simple or complex) was considered to be ‘be-
nign’, whereas atypical EH (simple or complex) was
considered to be ‘premalignant’.
For the studies using the EIN criteria, benign EH
was considered to be ‘benign’, whereas EIN was con-
sidered to be ‘premalignant’.
In two studies,16,19 some specimens categorised as EH
according to the WHO criteria were reclassified as cancer
according to the EIN criteria. These EHs were still included
as ‘premalignant’, because their exclusion would have cre-
ated a bias, as explained in detail in Data S1B.
If discrepancies between values reported in the text
and the tables were found, values from the tables
were used for the analysis.
In the analysis of sensitivity and specificity, the EH cate-
gory on preoperative biopsy was considered to be the index
test, whereas the presence of cancer at hysterectomy was
considered to be the reference test. The combination of
‘premalignant’ with ‘cancer’ was considered to be true
positive, the combination of ‘benign’ with ‘no cancer’ was
considered to be true negative, the combination of ‘benign’
with ‘cancer’ was considered to be false negative, and the
combination of ‘premalignant’ with ‘no cancer’ was con-
sidered to be false positive.
D A T A A N A L Y S I S
The prognostic value of the classification system was
assessed by calculating the odds ratio (OR), sensitivity
and specificity for each study and as a pooled esti-
mate, with a 95% confidence interval (CI). ORs for
the two systems were compared by use of the chi-
square test, with a significant P < 0.05. Results were
reported graphically in forest plots.
Statistical heterogeneity among studies was
assessed by use of the inconsistency index I2: hetero-
geneity was considered to be insignificant for
I2 < 25%, low for I2 < 50%, moderate for I2 < 75%,
and high for I2 ≥ 75%. In the case of I2 < 50%, a
fixed-effect model was used; otherwise, the random
effect model of DerSimonian and Laird was adopted.
Since the introduction of the EIN system, patholo-
gists have been influenced in their histological diag-
nosis of EH, regardless of the classification system
adopted. Among the included studies, the first study
using the EIN system was published in 2008. There-
fore, we excluded from the meta-analysis the studies
using the WHO system and published before 2008, to
obtain a balanced time frame.
REVIEW MANAGER 5.3 (The Nordic Cochrane Centre,
Cochrane Collaboration, 2014, Copenhagen, Denmark)
and META-DISC version 1.4 (Clinical Biostatistics Unit, Ramon
y Cajal Hospital, Madrid, Spain) were used for the analysis.
Results
S E L E C T I O N A N D C H A R A C T E R I S T I C S O F T H E
S T U D I E S
Eighteen studies with a total of 2527 EHs were
included in the systematic review.11–29 Fourteen stud-
ies used the WHO criteria, two used the EIN criteria,
© 2018 John Wiley & Sons Ltd, Histopathology, 74, 676–687.
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and two used both systems. The process of study
selection is shown schematically in Figure 1.
All studies were retrospective, although one
assessed a series from a previous prospective trial.
Three studies used a case–control design, whereas the
others were designed as retrospective series. The sam-
ple size ranged from 39 to 386. Sampling methods
for the index test included hysteroscopic biopsy,
curettage, pipelle biopsy, and vacuum aspiration.
The characteristics of the included studies are
shown in Table 1.
R I S K O F B I A S A S S E S S M E N T
The results of risk of bias assessment are shown in
Figure 2.
For the ‘patient selection’ domain, the risk of bias
was high for one study (case–control design28) and
unclear for two studies (selection criteria not speci-
fied); the remaining studies were considered to be at
low risk. Concerns about applicability were high for
four studies (study population composed of women
with EH at higher risk of progression12,16,19,20). The
reasons underlying the authors’ judgements are
explained in Data S1C.
For the ‘index test’ domain, one study was consid-
ered to be at high risk (simple EH without atypia
grouped together with simple atypical EH28), four
studies were considered to be at low risk (blinding to
reference standard), and the remaining studies were
considered to be at unclear risk (blinding not
reported).
Figure 1. Flow diagram of studies identified in the systematic review [Preferred Reporting Item for Systematic Reviews and Meta-analyses
(PRISMA) template].
© 2018 John Wiley & Sons Ltd, Histopathology, 74, 676–687.
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For the ‘reference test’ domain, one study was at
low risk (blinding to index test) and the remaining
studies were at unclear risk (blinding not reported).
For the ‘flow and timing’ domain, one study was con-
sidered to be at high risk (some patients underwent hys-
terectomy within 3 years from the EH biopsy22), seven
studies were considered to be at unclear risk (latency
time between EH biopsy and hysterectomy not clearly
reported, although it was stated that EH biopsies were
performed in the preoperative phase, implying a short
latency time), and the remaining studies were considered
to be at low risk (latency time of <1 year).
No further concerns about applicability were found.
R E S U L T S O F M E T A - A N A L Y S I S
Eleven studies were included in the meta-analysis,
owing to the exclusion of the two studies considered
to be at high risk of bias and the five studies pub-
lished before 2008.
Among nine studies assessing 1187 EHs according
to the WHO criteria (cytological atypia), the pooled OR
of coexistent cancer for premalignant EH versus benign
EH was 11.15 (95% CI 7.65–16.24), with low hetero-
geneity among studies (I2 = 32%) (Figure 3).
Among four studies assessing 507 EHs according
to the EIN criteria, the pooled OR was 11.85 (95% CI
Figure 2. A, Assessment of risk of bias: summary of risk of bias for each study. Plus sign: low risk of bias. Minus sign: high risk of bias.
Question mark: unclear risk of bias. B, Risk of bias graph for each risk of bias item presented as percentages across all included studies.
© 2018 John Wiley & Sons Ltd, Histopathology, 74, 676–687.
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4.91–28.62), with no heterogeneity among studies
(I2 = 0%) (Figure 3).
There was no statistical difference between the two
ORs (v2 = 0.02; P = 0.90) (Figure 3).
For the WHO criteria for premalignancy, the sensi-
tivity in predicting a concurrent cancer was 0.86
(95% CI 0.82–0.90), with moderate heterogeneity
(I2 = 55.8%), whereas the specificity was 0.67 (95%
CI 0.64–0.70), with high heterogeneity (I2 = 91.6%)
(Figure 4).
For the EIN criteria for premalignancy, sensitivity
was 0.98 (95% CI 0.94–0.99), with insignificant
heterogeneity (I2 = 11.9%), whereas the specificity
was 0.29 (95% CI 0.24–0.34), with high heterogene-
ity (I2 = 81.2%) (Figure 4).
Discussion
O R
Our study showed that the WHO and EIN systems
have similar prognostic value for the risk of cancer.
To the best of our knowledge, this is the first
meta-analysis comparing the WHO criteria and the
subjective EIN criteria for risk stratification in EH.
Our study attempted to address a long-standing issue.
The first problem with the former (1994) WHO sys-
tem was that EH had been separated into four cate-
gories on the basis of both cytological atypia and
glandular complexity.2,5 This classification did not
address the main question in EH diagnosis: how to
differentiate neoplastic lesions from reactive prolifera-
tions. The EIN system was proposed as a possible
solution to this problem, offering a dichotomous dif-
ferential diagnosis between benign EH and EIN.2,3,5,6
The 2014 WHO revision proposed a similar classifica-
tion into EH without atypia and atypical EH/en-
dometrioid intraepithelial neoplasia, overcoming this
major conceptual problem with EH diagnosis. This
revised classification reports ‘EIN’ as a synonym of
atypical EH.1 However, the WHO 2014 terminology
might be confounding, because the acronym ‘EIN’ is
used for ‘endometrioid intraepithelial neoplasia’.
Therefore, it is unclear whether it actually refers to
the EIN (endometrial intraepithelial neoplasia) system.
In fact, the WHO 2014 classification is not well inte-
grated with the EIN criteria, and appears to be based
too much on cytological atypia.
Figure 3. Forest plot of individual studies and pooled odds ratio for coexistent cancer with the World Health Organisation (WHO) and
endometrial intraepithelial neoplasia (EIN) classification criteria for endometrial hyperplasia.
© 2018 John Wiley & Sons Ltd, Histopathology, 74, 676–687.
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Regarding the prognostic value of premalignancy
criteria, several studies showed that the objective EIN
system with computerised calculation of the morpho-
metric D-score had a higher prognostic value than
the WHO system.6–8 However, use of the D-score is
not widespread, owing to the additional cost of a mor-
phometry workstation.5 Thus, it appears to be more
important to assess the prognostic value of the subjec-
tive EIN system, which may be easily introduced into
the routine histomorphological examination. In this
regard, evidence is lacking. In our meta-analysis, we
found that the ORs for a coexistent cancer were simi-
lar between the WHO system and the subjective EIN
system (11.15 and 11.85, respectively; P = 0.90). In
agreement with our results, a large study by Lacey
et al. published in 2008 showed that a collapsed WHO
system (based on cytological atypia alone, anticipating
the 2014 WHO revision) and the subjective EIN sys-
tem had similar accuracy in predicting the risk of can-
cer even in the long term (>1 year).32 These findings
suggest that the superiority of the EIN system over the
WHO system is lost when the criteria for premalig-
nancy are assessed subjectively.
Another major problem with the WHO system has
been the low reproducibility of the diagnosis of cyto-
logical atypia.33,34 Although this problem can be
eliminated by the use of objective computerised mor-
phometry, it remains when subjective criteria are
used. In fact, Ordi et al. showed that diagnosis made
with the subjective EIN system was also poorly
reproducible, with no significant difference from the
WHO system in interobserver agreement.35
Therefore, in the absence of further comparative
studies, it appears that there is no evidence to support
the superior reliability of the subjective EIN criteria
over the WHO criteria for risk stratification in EH.
S E N S I T I V I T Y A N D S P E C I F I C I T Y
Unlike the OR analysis, the analysis of sensitivity and
specificity showed significant heterogeneity among
studies. Such a finding is expected in meta-analyses
of diagnostic accuracy.36
Despite having similar overall reliability, the WHO
system and the EIN system showed different sensitiv-
ity and specificity. The excellent sensitivity of the EIN
system (0.98) indicates that it correctly classified
almost all EHs with coexistent cancer. The sensitivity
of the WHO system appeared to be lower (0.86),
implying that >10% of premalignant EHs were
missed. ‘Complex’ EH without atypia might account
for this discrepancy. ‘Complex’ refers to the complex-
ity of glandular architecture, which was a parameter
considered in the former WHO classification.2,37
Many complex non-atypical EHs did indeed meet the
EIN criteria for premalignancy.6,32,37
According to the RCOG guidelines, non-atypical
EHs may be treated by observation alone, progestins
being reserved for symptomatic cases. Furthermore,
the follow-up recommended for non-atypical EH is
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Figure 4. Forest plots of individual studies and pooled sensitivity and specificity for the World Health Organisation (WHO) (A) and endome-
trial intraepithelial neoplasia (EIN) (B) criteria for premalignancy in predicting a coexistent cancer in patients with endometrial hyperplasia.
[Colour figure can be viewed at wileyonlinelibrary.com].
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less close than that recommended for atypical EH.4
This might imply that >10% of precancerous EHs are
undertreated, increasing the risk of progression to
cancer. The conservative treatment of premalignant
EH has shown excellent outcomes, particularly with
hysteroscopic resection and/or medicated intrauterine
devices.38–40 Therefore, a highly sensitive diagnostic
method, such as the EIN system, may be more appro-
priate than the WHO system for the initial identifica-
tion of women who need to be treated.
On the other hand, the WHO system showed
higher specificity than the EIN system in predicting
the risk of coexistent cancer. This implies that,
among EHs without coexistent cancer, only a minor-
ity had cytological atypia, but most met the EIN crite-
ria for premalignancy. In this regard, cytological
atypia seems to characterise neoplastic EH in a more
advanced phase of carcinogenesis, resulting in it
being more specific for the risk of coexistent cancer.
Thus, a diagnosis of atypical EH might have a stron-
ger impact on prognosis than a diagnosis of EIN,
because of the risk of there being an already present
cancer rather than its neoplastic nature. In fact, the
percentages of occult cancer in atypical EH are often
>40%, with no significant difference if curettage is
chosen over hysteroscopic biopsy.41 For this reason,
the presence of cytological atypia might indicate the
need for closer and more careful follow-up in women
who are eligible for conservative treatment (e.g. 3-
monthly instead of 6-monthly), or a higher surgical
priority for women eligible for hysterectomy. A more
stratified diagnosis of premalignant EH may be crucial
in the assessment of eligibility for conservative treat-
ment in borderline cases, e.g. age Σ40 years, pluri-
parity, no wish to become pregnant in the short
term, and low couple fertility potential. In these cases,
the absence of cytological atypia might favour the
choice of a conservative treatment, owing to the
lower risk of cancer in the short term.
Besides these considerations, several other results
in the literature suggest that the EIN criteria and
cytological atypia have independent prognostic value.
In fact, Pavlakis et al. showed that the presence of
cytological atypia in EIN increases the risk of coexis-
tent cancer.20 On the other hand, Mutter et al.
observed that atypical EH was at higher risk of hav-
ing coexistent cancer when subjective EIN criteria
were met.16 Thus, each system might have its own
role and significance in the diagnostic process. The
possibility of integrating cytological atypia into the
EIN system as an independent parameter should be
considered. Basically, we would suggest classifying
EH according to the EIN criteria, and substratifying
the EIN diagnosis on the basis of the presence of overt
cytological atypia. In this way, three EH categories
would be identified: benign EH (polyclonal); EIN with-
out overt atypia (monoclonal, but with a lower risk
of coexistent cancer); and EIN with overt atypia
(monoclonal, with a higher risk of coexistent cancer).
A preliminary proposal for the clinical use of the two
systems integrated is shown as a flowchart in Fig-
ure 5. Further studies are necessary to confirm and
validate this diagnostic approach in the clinical
setting.
L I M I T A T I O N S
Our results may be limited by factors inherent to the
methodology of the included studies and factors
inherent to the topic assessed. In particular, the
methodology of most included studies might be biased
by the lack of blinding. Blinding in the index test was
reported in only four studies, and blinding in the ref-
erence standard in only one. Unclear risk of bias was,
indeed, assigned to most included studies with regard
to the index test and reference standard domains.
Regarding the topic assessed, a major limiting factor
might be the loss of patients with EH who did not
undergo hysterectomy. Such patients constitute the
majority of benign EH patients, who are usually trea-
ted conservatively. This also resulted in a dispropor-
tion between benign and premalignant EH in our
study population. The low reproducibility of EH
Figure 5. Flowchart showing the possible clinical use of cytological
atypia integrated into the endometrial intraepithelial neoplasia
(EIN) system.
© 2018 John Wiley & Sons Ltd, Histopathology, 74, 676–687.
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diagnosis, as discussed above, might be another
intrinsic limiting factor. Furthermore, the handling of
hysterectomy specimens is also affected by the index
diagnosis. In fact, if premalignant EH is the indication
for hysterectomy, the endometrial cavity may
undergo more extensive and accurate gross sampling.
However, as these limitations to be appear intrinsic to
the topic assessed, we did not consider them in the
risk of bias assessment.
Conclusion
Despite the reported superiority of the objective EIN
system based on computerised morphometry, the sub-
jective EIN criteria have reliability similar to that of
the WHO criteria in predicting the risk of coexistent
cancer in EH. However, whereas the EIN criteria
appear to be more sensitive in identifying neoplastic
EH even in an earlier phase, the WHO criterion of
cytological atypia seems to be more specific for high-
risk lesions. Therefore, integration of the EIN criteria
with cytological atypia may be considered, the first
being more appropriate for the initial selection of
patients for treatment (conservative or hysterectomy,
according to the age and desire for pregnancy), and
the second being more suitable for highlighting the
need for closer follow-up or higher surgical priority.
Further studies are necessary to confirm the clinical
applicability of this approach.
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